Lendeckel Uwe, Karimi Farzaneh, Al Abdulla Ruba, Wolke Carmen
Institute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, University of Greifswald, D-17475 Greifswald, Germany.
Biomedicines. 2023 Feb 28;11(3):724. doi: 10.3390/biomedicines11030724.
APN/CD13 is expressed in a variety of cells/tissues and is therefore associated with diverse physiological functions, including proliferation, differentiation, migration, angiogenesis, invasion, metastasis, vasoconstriction, and the regulation of normal and impaired immune function. Increased expression or activity of APN/CD13 has been described for various tumors, such that APN/CD13 is in most cases associated with reduced disease-free and overall survival. The mechanisms that mediate these cellular effects of APN/CD13 have been largely determined and are described here. APN/CD13-regulated signaling pathways include integrin recycling, the regulation of small GTPase activities, cell-ECM interactions, and Erk1/2, PI3K, and Wnt signaling. APN/CD13 is a neo-angiogenesis marker that is not found on normal endothelia, but it is found on neo-angiogenetically active endothelia. Therefore, APN/CD13 represents a specific receptor for so-called "tumor-homing peptides" (NRG peptides). Peptides containing the NRG motif show high-affinity binding to APN/CD13. APN/CD13 thus represents a versatile target for the inhibition of tumor-induced angiogenesis through the tumor-selective administration of, e.g., cytotoxic substances. Furthermore, it enables the molecular imaging of tumor masses and the assessment of (neo)angiogenesis in animal models and in patients. Pharmacological inhibitors of APN/CD13 have been proven to reduce tumor growth and tumor progression in various APN/CD13-positive tumors.
氨肽酶N/CD13在多种细胞/组织中表达,因此与多种生理功能相关,包括增殖、分化、迁移、血管生成、侵袭、转移、血管收缩以及正常和受损免疫功能的调节。已报道多种肿瘤中氨肽酶N/CD13的表达或活性增加,因此在大多数情况下,氨肽酶N/CD13与无病生存期和总生存期缩短相关。介导氨肽酶N/CD13这些细胞效应的机制已基本明确,在此进行描述。氨肽酶N/CD13调节的信号通路包括整合素循环、小GTP酶活性调节、细胞与细胞外基质的相互作用以及Erk1/2、PI3K和Wnt信号通路。氨肽酶N/CD13是一种新生血管生成标志物,在正常内皮细胞上未发现,但在具有新生血管生成活性的内皮细胞上可发现。因此,氨肽酶N/CD13代表了所谓“肿瘤归巢肽”(NRG肽)的特异性受体。含有NRG基序的肽与氨肽酶N/CD13表现出高亲和力结合。因此,氨肽酶N/CD13是通过肿瘤选择性给药(例如细胞毒性物质)抑制肿瘤诱导的血管生成的通用靶点。此外,它还能对肿瘤块进行分子成像,并在动物模型和患者中评估(新生)血管生成。已证实氨肽酶N/CD13的药理抑制剂可减少各种氨肽酶N/CD13阳性肿瘤的肿瘤生长和肿瘤进展。